Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

97 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical outcomes of early WT1 mRNA reduction after remission induction in newly diagnosed acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation.
Tsushima T, Kimeda C, Yoda N, Matsuo K, Tanaka K, Hatanaka Y, Matsumoto R, Shimoji S, Utsu Y, Masuda SI, Aotsuka N. Tsushima T, et al. Among authors: aotsuka n. Transplant Cell Ther. 2024 Dec 16:S2666-6367(24)00807-8. doi: 10.1016/j.jtct.2024.12.007. Online ahead of print. Transplant Cell Ther. 2024. PMID: 39694194 Free article.
Real-world effectiveness and safety of ibrutinib in patients with chronic lymphocytic leukemia in Japan: the Orbit study.
Muta T, Masamoto Y, Yamamoto G, Kurahashi S, Kameoka Y, Ota S, Matsuki E, Ozeki K, Toyama T, Takahashi N, Kumode T, Aotsuka N, Yoshimura T, Tamura H, Omi A, Shibayama K, Watanabe A, Isobe Y, Kojima K, Takizawa J, Nagai H, Suzumiya J, Aoki S. Muta T, et al. Among authors: aotsuka n. Int J Hematol. 2024 Nov 26. doi: 10.1007/s12185-024-03875-0. Online ahead of print. Int J Hematol. 2024. PMID: 39586984
Superior Survival After Unrelated Allogeneic Stem Cell Transplantation With Low-Dose ATG Compared to Low-Dose TBI in Myeloablative Fludarabine/Busulfan-Based Regimen for MDS on Behalf of the Adult MDS Working Group of the JSTCT.
Fujioka M, Itonaga H, Nakazawa H, Nishida T, Kataoka K, Ikeda T, Kako S, Matsuoka KI, Adachi K, Fujiwara SI, Aotsuka N, Kawakita T, Sakaida E, Kanda Y, Ichinohe T, Atsuta Y, Miyazaki Y, Ishiyama K. Fujioka M, et al. Among authors: aotsuka n. Transplant Cell Ther. 2024 Oct 6:S2666-6367(24)00693-6. doi: 10.1016/j.jtct.2024.09.026. Online ahead of print. Transplant Cell Ther. 2024. PMID: 39374663
Allogeneic stem cell transplant with TBI-based myeloablative conditioning in adolescents and young adults with Philadelphia chromosome-negative ALL treated with pediatric protocols.
Shimizu H, Kato J, Tanoue S, Kimura SI, Tachibana T, Hatano K, Usuki K, Taguchi J, Hagihara M, Tsukada N, Harada K, Takahashi S, Takada S, Sakaida E, Fujisawa S, Onoda M, Aotsuka N, Handa H, Hatta Y, Nakaseko R, Yano S, Ohashi K, Kanda Y; Kanto Study Group for Cell Therapy (KSGCT). Shimizu H, et al. Among authors: aotsuka n. Leuk Res. 2024 Sep;144:107562. doi: 10.1016/j.leukres.2024.107562. Epub 2024 Aug 20. Leuk Res. 2024. PMID: 39178610
A phase 1/2 study of NS-87/CPX-351 (cytarabine and daunorubicin liposome) in Japanese patients with high-risk acute myeloid leukemia.
Usuki K, Miyamoto T, Yamauchi T, Ando K, Ogawa Y, Onozawa M, Yamauchi T, Kiyoi H, Yokota A, Ikezoe T, Katsuoka Y, Takada S, Aotsuka N, Morita Y, Ishikawa T, Asada N, Ota S, Dohi A, Morimoto K, Imai S, Kishimoto U, Akashi K, Miyazaki Y; Study Group for NS-87/CPX-351. Usuki K, et al. Among authors: aotsuka n. Int J Hematol. 2024 Jun;119(6):647-659. doi: 10.1007/s12185-024-03733-z. Epub 2024 Mar 26. Int J Hematol. 2024. PMID: 38532078 Free PMC article. Clinical Trial.
Differential clinical impact of letermovir prophylaxis according to graft sources: a KSGCT multicenter retrospective analysis.
Toya T, Mizuno K, Sakurai M, Kato J, Mori T, Doki N, Masuda S, Aotsuka N, Tsukamoto S, Sakaida E, Nakajima Y, Fujisawa S, Machida S, Aoyama Y, Yokoyama H, Shono K, Hatta Y, Usuki K, Kataoka K, Kanda Y. Toya T, et al. Among authors: aotsuka n. Blood Adv. 2024 Mar 12;8(5):1084-1093. doi: 10.1182/bloodadvances.2023010735. Blood Adv. 2024. PMID: 38330190 Free PMC article.
97 results